Adicet Bio (ACET) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACET shares.
View ACET analyst ratings or view top-rated stocks.

4 analysts have issued 12 month price targets for Adicet Bio's stock. Their ACET share price forecasts range from $19.00 to $38.00. On average, they predict the company's stock price to reach $27.40 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ACET or view top-rated stocks among Wall Street analysts.

Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 38.7% and is now trading at $5.48.
View the best growth stocks for 2023 here.

Adicet Bio saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,930,000 shares, a decline of 7.6% from the April 30th total of 3,170,000 shares. Based on an average trading volume of 471,600 shares, the short-interest ratio is presently 6.2 days. Approximately 9.8% of the shares of the stock are short sold.
View Adicet Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ACET earnings forecast.

Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.16.

ETFs with the largest weight of Adicet Bio (NASDAQ:ACET) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Genomics Immunology and Healthcare ETF (IDNA) and Simplify Propel Opportunities ETF (SURI).iShares U.S. Tech Breakthrough Multisector ETF (TECB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include Marin Software (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

Adicet Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.91%), Carlyle Group Inc. (4.92%), Geode Capital Management LLC (1.41%), State Street Corp (1.31%), Dimensional Fund Advisors LP (1.30%) and Wellington Management Group LLP (1.17%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Chen Schor, Don Healey, Francesco Galimi and Jay P Elliott.
View institutional ownership trends.

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACET stock can currently be purchased for approximately $5.48.

Adicet Bio (NASDAQ:ACET) has a market capitalization of $235.42 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com.